Boehringer Makes Case For Interchangeable Adalimumab Biosimilar
Voltaire-X Switching Study Concludes Similar Clinical Outcomes
Boehringer Ingelheim, which is looking to be among the limited players to offer an interchangeable biosimilar in the US, has reported positive switching data from the company’s “first-of-its-kind” Phase IIIb Voltaire-X study.
